Hematologic Diseases Clinical Trial
Official title:
Naturopathic-pharmacological Consultation on the Use of Dietary Supplements in Patients With Hematological Diseases
NCT number | NCT05982262 |
Other study ID # | 0149-20-BNZ |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 15, 2023 |
Est. completion date | June 2028 |
The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. The main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients. Participants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. Some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 2028 |
Est. primary completion date | December 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Followed up for a hematological condition 2. Ability to fill simple questionnaires in Hebrew, Russian or Arabic 3. Indication for consultation: 1. Patient's request to expand knowledge about the use of DHS 2. Patient using DHS 3. Patient's desire to start using DHS 4. Patient that is interested in hearing about the use of DHS for his/her health condition 5. Medical or nursing team's recommendation to take DHS for medical treatment or to improve compliance with conventional treatment. Exclusion Criteria: None |
Country | Name | City | State |
---|---|---|---|
Israel | Bnai Zion Medical Center | Haifa |
Lead Sponsor | Collaborator |
---|---|
Bnai Zion Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of the use of DHS in patients with a hematological disease through naturopathic counseling | Number of potential interactions with moderate to major level of significance prevented by the naturopathic consultation in each patient, as well as the incidence of DHS-related safety events. The Naranjo and modified Food and Drug Administration algorithm will be used to assess the causality of such events with the specific dietary supplements, and only side effects at least possibly caused by the DHS according to these scales will be considered. | From enrollment to the end of intervention, up to 1 year | |
Secondary | Efficacy of prescribed dietary and herbal supplements (DHS) | Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire: requires participants to nominate one or two concerns and, using a seven-point scale from 0 (worse outcome) to 6 (best outcome), to score these concerns and their general feeling of wellbeing. | From enrollment to the end of intervention, up to 1 year | |
Secondary | Patient-physician communication around the use of DHS | Asking the patient whether the topic has been brought up with the treating hematologist and checking the documentation of the use of DHS in the medical charts | From enrollment to the end of intervention, up to 1 year | |
Secondary | Patient satisfaction | Direct question asked after each meeting ranking in a 1-5 Likert scale the satisfaction of the patient from the consultation: from 1 (not satisfied at all) to 5 (maximal satisfaction) | From enrollment to the end of intervention, up to 1 year | |
Secondary | Compliance with hematological treatment | Relative dose intensity (RDI) of the prescribed hematological drugs both before and after intervention: The term of dose intensity (DI) is used to define the drug dose delivered per time unit and is expressed as mg/m2 per week. A delay in the sequence of treatment cycles decreases the DI in the same proportion as a reduction of dose. Average relative DI corresponds to the mean DI of combined agents and is expressed as a fraction of a similar combination selected as a standard | From enrollment to the end of intervention, up to 1 year | |
Secondary | Qualitative evaluation of the staff and patients from naturopathic-pharmacological counseling | Semi-structured in-depth interviews will be conducted with patients who are interested in participating in the qualitative arm (10-15 patients) and the staff members involved (medical staff, nursing staff, naturopath, clinical pharmacist). The goal is to describe the process of building the naturopathic-pharmacological consultation and evaluate the satisfaction of the staff and patients | From enrollment to the end of intervention, up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04094844 -
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
|
N/A | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01445561 -
Ultra Low Dose Interleukin-2 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Completed |
NCT04168983 -
Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy
|
N/A | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT01108159 -
Integrated Whole-Genome Analysis of Hematologic Disorders
|
||
Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
Completed |
NCT00213239 -
A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
|
Phase 1/Phase 2 | |
Terminated |
NCT00208949 -
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
|
Phase 2 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT00208962 -
Allogeneic Cell Therapy for Adults With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05487794 -
Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis
|
N/A | |
Completed |
NCT03611257 -
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
|
N/A | |
Completed |
NCT02827149 -
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
|